Eyenovia is at the forefront of ophthalmic therapy innovation with its Optejet® technology, which offers a unique alternative to traditional eye drops. The Optejet® is the only FDA-approved ophthalmic spray that allows for the precise delivery of medication through a gentle mist, significantly enhancing the patient experience. This device is designed to dispense an appropriate microdose of medication—specifically 8μL—thereby minimizing drug overflow and reducing the risk of overdosing. Clinical studies have demonstrated high success rates in self-administration and technician-assisted use, highlighting its user-friendly design that caters to both patients and caregivers.

In addition to its innovative delivery system, Eyenovia is developing the Optecare™ digital technology suite, which aims to improve patient adherence and chronic disease management. This technology will enable real-time monitoring of medication compliance and provide valuable data to healthcare providers, facilitating more personalized treatment plans. The combination of the Optejet® and Optecare™ technologies not only enhances the therapeutic profile of existing and new drug solutions but also aims to reduce systemic exposure and toxicity, ultimately leading to better patient outcomes in ophthalmic care.

United States

Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases. 

Eye Diseases

Eyenovia

Eye disease

MicroStat is Eyenovia's first-in-class fixed-combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation) which is targeted to address the growing needs of the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. We are developing MicroStat to help improve efficacy, usability and tolerability of pharmacologic mydriasis.

MYDCOMBI™ (trop+phen) (MicroStat)

Utilizes one of the most potent corticosteroids and innovative APNT™ nanoparticle formulation technology in a novel ophthalmic application.&nbsp;

Clobetasol propionate ophthalmic suspension 0.05%  (APP13007)

Eyenovia’s MicroLine is a proprietary microdosed formulation of pilocarpine for presbyopia that is delivered via the Company’s <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Feyenovia.com%2Ftechnology-2019%2F&amp;esheet=52349507&amp;newsitemid=20201216005342&amp;lan=en-US&amp;anchor=Optejet+dispenser&amp;index=3&amp;md5=fc783001ba255c9fa08fd72ad8446d80" rel="nofollow">Optejet dispenser</a>. Providing high precision microdosing at approximately 1/5th the drug volume of a traditional eyedropper, the Optejet is designed to deliver targeted, consistent doses more conveniently than typical eyedroppers.

Eyenovia

Company Details